Skip to main content Help with accessibility Skip to main navigation

RIVAROXABAN 2.5mg tablets (Xarelto®▼) for Acute Coronary Syndrome

Last Updated: 24 May 2017

Body System: Cardiovascular system

Amber initiated

The Pan Mersey Area Prescribing Committee recommends the prescribing of Rivaroxaban 2.5mg tablets (Xarelto®▼) following specialist initiation for preventing adverse outcomes after acute management of acute coronary syndrome in accordance with NICE TA335.